[go: up one dir, main page]

CO2019006693A2 - Improved composition of lansoprazole and simethicone and process to prepare it - Google Patents

Improved composition of lansoprazole and simethicone and process to prepare it

Info

Publication number
CO2019006693A2
CO2019006693A2 CONC2019/0006693A CO2019006693A CO2019006693A2 CO 2019006693 A2 CO2019006693 A2 CO 2019006693A2 CO 2019006693 A CO2019006693 A CO 2019006693A CO 2019006693 A2 CO2019006693 A2 CO 2019006693A2
Authority
CO
Colombia
Prior art keywords
simethicone
lansoprazole
prepare
improved composition
microgranules
Prior art date
Application number
CONC2019/0006693A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CO2019006693A2 publication Critical patent/CO2019006693A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de administración oral, que comprende la combinación a dosis fija de Simeticona en microgránulos de alta concentración y Lansoprazol o su enantiómero (Dexlansoprazol) en microgránulos de liberación entérica y el proceso para obtener los microgránulos de alta concentración de Simeticona.The present invention relates to a pharmaceutical composition for oral administration, comprising the fixed dose combination of Simethicone in high concentration microgranules and Lansoprazole or its enantiomer (Dexlansoprazole) in enteric release microgranules and the process for obtaining high concentration microgranules. of Simethicone.

CONC2019/0006693A 2016-12-14 2019-06-21 Improved composition of lansoprazole and simethicone and process to prepare it CO2019006693A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016016587A MX385008B (en) 2016-12-14 2016-12-14 IMPROVED COMPOSITION OF LANSOPRAZOLE AND SIMETHICONE AND PROCESSES FOR PREPARING THEM.
PCT/IB2017/057904 WO2018109693A1 (en) 2016-12-14 2017-12-13 Improved composition of lansoprazole and simeticone and method for preparing same

Publications (1)

Publication Number Publication Date
CO2019006693A2 true CO2019006693A2 (en) 2019-07-10

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006693A CO2019006693A2 (en) 2016-12-14 2019-06-21 Improved composition of lansoprazole and simethicone and process to prepare it

Country Status (8)

Country Link
AR (1) AR110183A1 (en)
CL (1) CL2019001462A1 (en)
CO (1) CO2019006693A2 (en)
CR (1) CR20190290A (en)
DO (1) DOP2019000145A (en)
MX (1) MX385008B (en)
PE (1) PE20191654A1 (en)
WO (1) WO2018109693A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
CA2858821A1 (en) * 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation

Also Published As

Publication number Publication date
CL2019001462A1 (en) 2019-08-23
MX2016016587A (en) 2018-06-13
DOP2019000145A (en) 2019-08-15
CR20190290A (en) 2019-11-18
AR110183A1 (en) 2019-03-06
BR112019011966A2 (en) 2019-11-05
PE20191654A1 (en) 2019-11-07
WO2018109693A1 (en) 2018-06-21
MX385008B (en) 2025-03-14

Similar Documents

Publication Publication Date Title
CY1124548T1 (en) MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS
CY1122786T1 (en) DOSAGE FORMS FOR Echinocandin Class Compounds
CY1122792T1 (en) MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS
MX2021008113A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN IL-4R ANTAGONIST FOR USE IN THE TREATMENT OF ASTHMA.
PE20151301A1 (en) PHARMACEUTICAL FORMULATIONS RESISTANT TO IMPROPER HANDLING
JOP20180025A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CL2017001026A1 (en) Methods and compositions particularly for the treatment of attention deficit disorder.
AR128459A2 (en) ROLLER-COMPRESSED SOLID PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS MANUFACTURE
CL2016002560A1 (en) Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
MX2018015022A (en) Methods for treating alzheimer's disease.
MX387731B (en) ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE.
MX392182B (en) FIXED-DOSE COMBINATIONS AND FORMULATIONS COMPRISING 8-HYDROXY-2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID (ETC1002) AND EZETIMIBE AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE.
MX385518B (en) FORMULATION HAVING ENHANCED pH-DEPENDENT DRUG RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
BR112018074655A2 (en) fosnetupitant injectable formulation and method of manufacturing a formulation
AR108233A1 (en) ORIC PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
MX385513B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING SAFINAMIDE.
CO2019006693A2 (en) Improved composition of lansoprazole and simethicone and process to prepare it
ECSP19044926A (en) IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING
UY37413A (en) OPROZOMIB IMMEDIATE RELEASE FORMULATIONS
MX2015007749A (en) Pharmaceutical composition of amanthadine hydrochloride-loratadin e-paracetamol in a capsule for treating colds amongst other allopathy.
CO2019008347A2 (en) Quick release composition of cinitapride and simethicone and process to prepare it
MX2017002700A (en) Pharmaceutical composition for the treatment of acute tooth or jaw pain.